US 12,290,606 B2
Method for producing a drug delivery system
Achim Schneeberger, Vienna (AT); Klaus Kühne, Berlin (DE); Helmut Kerschbaumer, Zürich (CH); and Srdan Vasic, Horgen (CH)
Assigned to Laxxon Medical AG, Stetten (CH); and Exentis Knowledge GmbH, Stetten (CH)
Filed by Laxxon Medical AG, Stetten (CH); and Exentis Knowledge GmbH, Stetten (CH)
Filed on Aug. 15, 2022, as Appl. No. 17/819,940.
Application 17/819,940 is a division of application No. 16/958,768, granted, now 11,484,504, previously published as PCT/EP2017/084828, filed on Dec. 29, 2017.
Prior Publication US 2023/0078273 A1, Mar. 16, 2023
Int. Cl. A61K 9/20 (2006.01); A61K 9/70 (2006.01); A61P 31/00 (2006.01); B41M 1/18 (2006.01); A61K 45/06 (2006.01)
CPC A61K 9/2095 (2013.01) [A61K 9/2077 (2013.01); A61K 9/7092 (2013.01); A61K 45/06 (2013.01)] 33 Claims
OG exemplary drawing
 
1. A method for producing a drug delivery system, the method comprising:
screen-printing a base paste;
curing the base paste;
screen-printing a first paste separate to the base paste;
curing the first paste;
wherein the first paste comprises a therapeutically effective amount of a first active pharmaceutical ingredient, API;
wherein the base paste and the first paste are soluble in body fluids such that the resulting drug delivery system is soluble in body fluids;
wherein the pastes are screen-printed such that in the resulting drug delivery system the first paste is inhomogeneously arranged in the base paste;
wherein the pastes are screen-printed such that the base paste is provided as a three-dimensional body and the separate first paste is inhomogeneously arranged throughout the base paste along the three dimensions;
wherein the pastes are screen-printed such that in the resulting drug delivery system the concentration of the first API varies throughout the drug delivery system;
wherein a transition from an area in the drug delivery system with a high API concentration to an area in the drug delivery system with a low API concentration is smooth;
wherein the concentration profile of the first API is such that upon application of the drug delivery system the release of the first API occurs at a varying rate; and
wherein the first API is a CNS agent.